Webinar | Intra-Aortic Balloon Pumps (IABP)| December 22, 2015

Webinar: Hemodynamics of Counterpulsation

This webinar is sponsored by Maquet

IABP

The webinar "Hemodynamics of Counterpulsation" explained how the intra-aortic balloon pump (IABP) can increase diastolic aortic pressure and augment coronary blood flow and reduce aortic and left ventricular systolic pressure or afterload. This education offering provides a review of the physiologic benefits, evaluation of patient response, discusses how patients may derive the most benefit and offers practical technical components to optimize IABP therapy.


The live webinar was Jan. 28, 2016, but a recorded version is available on demand.  
Register for the on demand webinar


Statement of Purpose/Need: 

The Intra-aortic balloon pump (IABP) has been the first-line choice for mechanical circulatory support around the world due to its clinical efficacy, safety profile across a broad range of patient care scenarios, and low cost. IABP therapy is the most widely used nondurable mechanical circulatory support device (MCS), with more than 160,000 IAB catheters placed globally per a year. The primary goals of the IABP are to (1) increase diastolic aortic pressure and augment coronary blood flow, and (2) reduce aortic and left ventricular systolic pressure or afterload. This education offering will provide a review of the physiologic benefits, evaluate patient response, discuss what patients may derive the most benefit and practical technical components to optimize IABP therapy.


After completing the webinar, the participant should be able to::


• Assess the physiologic effects of Intra-aortic balloon counterpulsation (IABP) therapy

• Understand the clinical utility of IAB use

• Describe the factors that effect IAB catheter performance and benefits of larger-capacity IAB catheters


Speaker:



Atman P. Shah 

Associate Professor of Medicine 

Clinical Director, Section of Cardiology 

Co-Director, Cardiac Catheterization Laboratory


Atman P. Shah, M.D., is an interventional cardiologist at the University of Chicago. Shah's research efforts focus on improving survival rates in patients who have experienced a cardiac arrest or an acute myocardial infarction (heart attack). Additionally, he studies new therapies that can help save heart muscle during a heart attack. Shah is the primary investigator on a number of large multicenter clinical trials investigating novel medications and devices designed to improve the quality of life in patients with coronary artery and structural heart disease. Shah has authored six book chapters and more than 50 abstracts and publications. A dedicated educator, he trains medical students, residents and fellows. He is the recipient of several honors and awards for clinical service, leadership and teaching.


About Maquet Medical Systems

Since 1838, the Maquet brand has been synonymous with high-quality products for patient-focused care. Maquet is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. Cardiovascular specialties include intra-aortic balloon counterpulsation therapy for cardiac assist; coronary artery bypass surgery; aortic and peripheral vascular surgery; and extracorporeal circulation. Maquet continuously strives to develop innovative technologies that enhance clinical expertise and improve healthcare economics, while also enabling medical professionals to achieve the best possible outcomes for all patients.


For more information please visit www.maquet.com



Register for the on demand webinar


Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init